Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: Still not ready for routine clinical use

Journal of Clinical Oncology

Volumn 22, Issue 19, 2004, Pages 3842-3845

  Toner, Guy C ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CHORIONIC GONADOTROPIN; TUMOR MARKER; BIOLOGICAL MARKER;

CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; EDITORIAL; HUMAN; MALE; MULTIVARIATE ANALYSIS; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; TESTIS CANCER; TREATMENT FAILURE; TREATMENT OUTCOME; BLOOD; GERM CELL TUMOR; NOTE; TESTIS TUMOR; TIME;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; GERMINOMA; HUMANS; MALE; TESTICULAR NEOPLASMS; TIME FACTORS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 5444232585     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.923     Document Type: Editorial

References (26)

1. Ries LAG, Eisner MP, Kosary CL, et al: SEER cancer statistics review, 1975-2001. Bethesda, MD, National Cancer Institute. http://seer.cancer.gov/csr/ 1975_2001/
2. Fizazi K, Culine S, Kramar A, et al: Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis non-seminomatous germ-cell tumors. J Clin Oncol 22:3868-3876, 2004
3. International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997
4. Lange PH, Vogelzang NJ, Goldman A, et al: Marker half-life analysis as a prognostic tool in testicular cancer. J Urol 128:708-711, 1982
5. de Wit R, Collette L, Sylvester R, et al: Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer 78:1350-1355, 1998
6. Gerl A, Lamerz R, Clemm C, et al: Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors. Clin Cancer Res 2:1565-1570, 1996
7. Mazumdar M, Bajorin DF, Bacik J, et al: Predicting outcome to chemotherapy in patients with germ cell tumors: The value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 19:2534-2541, 2001
8. Skipper HE: Kinetics of mammary tumor cell growth and implications for therapy. Cancer 28:1479-1499, 1971
9. Thompson DK, Haddow JE: Serial monitoring of serum alpha-fetoprotein and chorionic gonadotropin in males with germ cell tumors. Cancer 43:1820-1829, 1979
10. Vogelzang NJ, Lange PH, Goldman A, et al: Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 42:4855-4861, 1982
11. Picozzi VJ Jr, Freiha FS, Hannigan JF Jr, et al: Prognostic significance of a decline in serum human chorionic gonadotropin levels after initial chemotherapy for advanced germ-cell carcinoma. Ann Intern Med 100:183-186, 1984
12. Horwich A, Peckham MJ: Serum tumour marker regression rate following chemotherapy for malignant teratoma. Eur J Cancer Clin Oncol 20:1463-1470, 1984
13. Carl J: Drug-resistance patterns assessed from tumor marker analysis. J Natl Cancer Inst 81:1631-1639, 1989
14. Toner GC, Geller NL, Tan C, et al: Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 50:5904-5910, 1990
15. Murphy BA, Motzer RJ, Mazumdar M, et al: Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 73:2520-2526, 1994
16. Stevens MJ, Norman AR, Dearnaley DP, et al: Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol 13:87-92, 1995
17. de Wit R, Sylvester R, Tsitsa C, et al: Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: A study in patients with disseminated non-seminomatous testicular cancer. Br J Cancer 75:432-435, 1997
18. Gerl A, Lamerz R, Mann K, et al: Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors? Anticancer Res 17:3047-3049, 1997
19. Inanc SE, Meral R, Darendeliler E, et al: Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors. Acta Oncol 38:505-509, 1999
20. Motzer RJ, Mazumdar M, Gulati SC, et al: Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828-1835, 1993
21. Motzer RJ, Mazumdar M, Bajorin DF, et al: High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15:2546-2552, 1997
22. See WA, Cohen MB, Hoxie LD: Alpha-fetoprotein half-life as a predictor of residual testicular tumor: Effect of the analytic strategy on test sensitivity and specificity. Cancer 71:2048-2054, 1993
23. 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13:1356-1363, 2002
24. Kostakoglu L, Coleman M, Leonard JP, et al: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027, 2002
25. Collette L, Sylvester RJ, Stenning SP, et al: Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma: European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91:839-846, 1999
26. Feuer EJ, Sheinfeld J, Bosl GJ: Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. J Natl Cancer Inst 91:816-818, 1999